... Updated the target price from $216 to $225...! I'm not sure I'm following here? Have they been stored in one of Regeneron's -80C freezers for the past 3 months?! how valuable is this information? All lights are green for REGN, the PPS has been north of $240 for the past 6 months, the company keeps beating all analysts estimates with their revenues, raising sales' forecast each and every time, and the pipeline is the hottest of the Biotech field.
I want a job at Cowen!
I've been long REGN fro the past few years, since the pps was in its 20s...
so I'm not sure who's the fool here, but you should keep your insults to yourself. It's very easy to come with name behind a keyboard, but watch your mouth; it doesn't make you much of a genius.
everybody here knows that the stock will be close to the target price of $300 by year end.
I find fascinating that a stock can be manipulated like that by some who benefit in both directions. "worthless bag" is kind of overstated for a company that generates over $1 billion in sales already, and is about to unleash 2 new blockbusters in the next 2 years, don't you think?
what does it have to do with the business itself...?! most analysts raised their target price over $300, based on forecast revenues and a strong pipeline. who is selling? seriously?!
...seems like we are entering the handle part of a new cup and handle. Based on the high of $282 and the low of $215, the upside could be huge for this one. $330-$340 is a possible short term target if we cross $280 again. Soughts?
If you start a post claiming that you are an Ophthalmologist, make sure to know how to spell EYLEA (even more if you are "very familiar with it")!
Since we are talking about potential take over, I have some hard time to understand why it is taking so much time for Sanofi or Bayer to make a move. Sanofi has this amazing partnership with REGN, financing most of discovery, but are missing on the sweet right now (Eylea). On another hand, Bayer enjoys amazing revenues from a single drug partnered with Regeneron, but is about to miss on the upcoming huge success of REG727 and Dupilumab... I don't believe that either of the giants would be happy with only a slice of the cake, considering that they both face threat from generics with their own source of revenues. Not to mention that the status quo could bring a third player in the game. Just to say that it is a good time to own REGN!
Do you really think management would consider a buyout with a 20% premium over the actual market cap in such a prosperous time for the company? there is 2 drugs coming up (we all know what they are, no need to explain here), that might hit blockbuster status faster than Eylea. The stock could easily hit $350-$400 by the end of 2014 just by taking into consideration the future sales forecast.
I'm afraid $500/$550 is the next "acceptable" offer. Genentech was absorbed for over $40Bil. I can see this happening for REGN too!
...I've been waiting for that day for so long now... It has finally arrived. As many, I have been fooled a few years ago by a CEO con artist, who used his skills for too many years now. Hiding/lying/manipulating worked well until today. It is sad that someone paid with his/her life. Lets hope this horrific event will put a final stop to this scam company.
usually companies go bankrupt, not stocks...
anyways, the "PT at $25" thing was funny.
you have absolutely no clue, do you?!
And you are freaking out because of the good news that keep coming. Why don't you just shut the hell up, stop insulting people on this board, and do your own thing that makes more financial sense to you?
Regeneron is a remarkable company my friend, with some of the most respectable scientists in the world. The REGN story is only starting. sorry if you cant see that. I would recommand you to quickly find yourself another sandbox.Enjoy your day.
You know what crkenmore, you have a point. investment strategies are diverse and personal. Wishing you best of luck with yours. I guess we will both be selling some positions at $300 a few months from now! ;)
of course you guy (s) are agreeing with each others, considering that you are shorting the stock. what about $120 for a correction?! sounds better? Corporate officers have been selling the stock at the same pace, they are scheduled sales. "absorb the pain"!? what are you talking about?! you have to be out of your mind to sell REGN now, or unaware of the reason why you have invested in the first place. who cares about what the stock price will be 5, 10, 15 days from now.
don't look at it. we have been going through this pattern a couple of times already. usually 10-12 days of correction after a run up. the last one took us from $180 beginning of April to $284. The consensus on the stock is "buy" and price targets for most financial institutions are above $300. As long as you know what you are in for, there is nothing to worry about.
Nope. They are the ones forcing the drop since May 14. They are taking profits on both sides. amazing what you can do when you have the financial power. going from $283 to $245 in such a short period of time has to be manipulation or a failed drug when it comes to Biotech. Considering that we only have heard good news from REGN and its pipeline, it doesn't take a rocket scientist to describe what's going on here.
they are making a little more than "some nickels", but I completely agree with you regarding the manipulators. I think we're not done yet going down. we might reach $230-$240. But that's great. another "cup and handle" will form. the deeper the cup, the better the upside! ;)
Eatlogic, the 10% down came just after a whooping 35% up starting end of April. So of course there is some profit taking.
At the end of the day, what will continue to drive the stock up is the science coming out of REGN. And we all know it's there.
To be honest, I don't think REGN's strategy is to buy other's technologies. The management has an history of building pride with their own scientific approaches, and to stick to it. The trap technology could have been a disaster, they turned it around for what is now a blockbuster drug! In the contrary, we shall see the company being acquired in the near future. Hard to put a timeline, but it is in my opinion the most obvious outcome.The pie is big now, but there is always enough appetite for such an amazing biotech pipeline. Just Eylea and its future new applications (DME is as big as Wet AMD in term of expected revenue) could make sense for an acquisition. REGN727 and now REGN668 confirming itself as a safe and (very) potent antibody are cherries on the cake.
wouldn't you call the positive data from the PhaseII of Dupilumab a positive catalyst!?
Wouldn't you call UBS' $290 or Roth Capital's $314 price targets a good reason to think that REGN is going to consolidate around its high of $280...?
There is no stress on the stock. I think it is the last attempt from top players to load up before acquisition. They have been doing a great job at correcting the pps these past few days, but the down trend party is almost over. your $214 consolidation is on the low side. We might see $230-$240 before this summer. but all lights are green with the company. it is just a question of timing. will REGN be acquired before the next blockbusters are cleared by the FDA? If not, the stock will hit $300 before year ends.
You know what, that type of post is as instructive as the ones saying that REGN is some kind of trash... there is no buyout O/N, certainly not at $1000 if happening. lets stay with the facts and try to bring some sense to that board!